Class IIITerminated in FDA datasetRecall initiated Jun 10, 2013

Max Blood Sugar Defense 150 tablets Dietary Supplement Product labeling reads in part:"*DIETARY…

Recalling firm: Healthmaxx Global Inc.

Why it was recalled

In response to a FDA inspection, the firm initiated this voluntary recall of various dietary supplements due to the following problems of mislabeling: 1) product named on the…

Historical recall record. This is not a new recall announcement. “Terminated” describes the FDA recall process; it does not certify that an individual package is safe. FDA termination date: Nov 14, 2014.

Check your package

Compare the exact product and package details with the label you have.

ProductMax Blood Sugar Defense 150 tablets Dietary Supplement Product labeling reads in part:"*DIETARY SUPPLEMENT 150 tablets***Manufactured for:HealthMax Products Inc. Altadena, CA 91001***".UPC 6 65176 52047 1
UPC665176520471

FDA code information

Lot# D0915

Match the product, package size, and code together. A missing match does not guarantee safety.

Full FDA record and distribution details

Original product description

Max Blood Sugar Defense 150 tablets Dietary Supplement Product labeling reads in part:"*DIETARY SUPPLEMENT 150 tablets***Manufactured for:HealthMax Products Inc. Altadena, CA 91001***".UPC 6 65176 52047 1

Extracted codes and context

TypeCode / valueContext
UPC6651765204710 tablets***Manufactured for:HealthMax Products Inc. Altadena, CA 91001***".UPC 6 65176 52047 1
lotD0915Lot# D0915

Original FDA recall reason

In response to a FDA inspection, the firm initiated this voluntary recall of various dietary supplements due to the following problems of mislabeling: 1) product named on the label is not actual product contained; 2)ingredients listed are not actual ingredients contained.

Recall details

Recall number
F-1941-2013
Event ID
65733
FDA status
Terminated
Initiated
Jun 10, 2013
Reported
Oct 2, 2013
Classified
Sep 24, 2013
Terminated
Nov 14, 2014
Quantity
Unknown
Location
Hacienda Heights, CA, United States
Initiation type
Voluntary: Firm initiated
Notification
Letter

Where it was distributed

CA, MD, and NY

FDA source record · F-1941-2013

Data updated September 16, 2026. View official FDA data ↗

Follow official FDA and manufacturer guidance.